With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
To appear in our next issue, send your Business and Financial News stories to
gwyneth@intlabmate.com The latest business developments from across Europe & Middle East
by Gwyneth Astles
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Key partnerships unlock protein access across APAC and the Middle East
Biotech fi rm Nuclera is accelerating its commercial momentum with a major move into Asia-Pacifi c and Middle Eastern markets through a network of new distribution agreements. The Cambridge-based company, known for its eProtein Discovery™ System that simplifi es and speeds up protein expression, has signed partnerships across China, Japan, South Korea, Singapore, Taiwan, and Israel.
The expansion refl ects Nuclera’s shift from early-stage innovation to global commercial execution. Its new regional partners - including MineBio Life Sciences (China), Kiko Tech (Japan), Chayon Laboratories (South Korea), Sciencewerke (Singapore), Cold Spring Biotech (Taiwan), and Yair Or Technologies (Israel) - will provide localised sales and technical support
to a growing customer base in pharma, biotech, and academia.
With protein targets underpinning most modern drug discovery efforts, demand is rising for tools that take the complexity out of producing high-quality, functional proteins. Nuclera’s platform enables researchers to move quickly from gene to protein using a compact,
automated “This benchtop system that supports both
cell-free and cell-based workfl ows - now including membrane proteins.
is a major step forward in making protein
expression faster and more accessible for scientists globally,” said Dr Michael Chen, Nuclera CEO and co- founder. “Our presence in these new markets allows us to better serve customers where they are, through trusted local partners.”
The move follows Nuclera’s recent Series C fundraising and the fi rst CRO installation of its system - milestones that signal strong commercial traction.
Chief Commercial Offi cer Joseph Bertelsen added: “Building these partnerships is about more than footprint - it’s about enabling hands-on support and scaling our customer relationships in high-potential markets. We’re excited to see where this next phase of growth takes us.”
More information online:
ilmt.co/PL/Gw6j 64670pr@reply-direct.com
New leadership to accelerate healthcare sector growth
Ken Shinomiya.
Asahi Kasei has named Ken Shinomiya as the new leader of its Healthcare Sector, following Richard Packer’s tenure. Shinomiya, previously President of Asahi Kasei Life Science, brings a wealth of experience and a strategic vision for advancing the company’s healthcare portfolio. Under his leadership, Asahi Kasei aims to accelerate its global growth in pharmaceuticals, life sciences, and critical care, further enhancing its commitment to improving patient outcomes worldwide.
Swiss pharma manufacturing to expand with CHF 25.5 million investment
CARBOGEN AMCIS, a Swiss pharmaceutical process development and API manufacturing company, has announced a major co-investment exceeding CHF 25 million to expand its production capabilities at its Aarau and Neuland sites in Switzerland. This strategic move supports increased demand for a drug linker used in a commercial antibody-drug conjugate (ADC).
The investment includes signifi cant upgrades to both sites. At Aarau, new 850-litre reactors and 0.4 m² agitated fi lter dryers will be installed, with completion targeted for the fi rst quarter of 2027. Meanwhile, the Neuland site will see similar equipment additions, expected to be operational by the third quarter of 2027.
This expansion builds on a previous joint funding effort from 2021, reinforcing the long-term collaboration between CARBOGEN AMCIS and its Japanese customer. The partnership highlights a shared commitment to scaling up production to meet the evolving needs of complex, high- value pharmaceutical compounds.
Stephan Fritschi, CEO of CARBOGEN AMCIS, emphasised the company’s ability to grow alongside its customers: “This investment allows us to respond to rising demand for advanced therapies such as ADC drug linkers while maintaining our technical excellence and operational standards.”
Known for its expertise in handling highly potent compounds, CARBOGEN AMCIS provides comprehensive services from process development through commercial manufacturing. The new equipment and infrastructure upgrades will enhance the company’s capacity to deliver
The CARBOGEN AMCIS Bubendorf HQ.
high-quality, cGMP-compliant manufacturing solutions in line with global regulatory requirements.
Carl Baker, Vice President of the Business Unit Drug Substance, added: “Upgrading our Aarau and Neuland facilities ensures we can meet increasing production volumes without compromising containment controls and operational quality.”
With additional sites in France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint, providing integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.
More information online:
ilmt.co/PL/0ZmW 64890pr@reply-direct.com
Shinomiya’s journey in the healthcare industry includes
signifi cant roles, such as Vice President of Strategy at ZOLL Medical and Head of the Bioprocess Division at Asahi Kasei Medical. He became President of Asahi Kasei Medical in 2023, and later President of Asahi Kasei Life Science, where he led the expansion of the company’s life sciences business. This included the addition of essential services like contract research and biologics development, as well as the acquisition of Bionova Scientifi c in the US.
Asahi Kasei’s Healthcare Sector has seen signifi cant globalisation, particularly since its acquisition of ZOLL Medical in 2012, which established a strong presence in the U.S. critical care market. The sector’s continued global expansion is supported by targeted investments, including mergers and acquisitions, and strategic moves like the relocation of the company’s headquarters to the US in 2023.
With Shinomiya at the helm, Asahi Kasei’s Healthcare Sector is poised to continue its long-term growth strategy, aiming for operating income of ¥150 billion by 2030. “Our healthcare business exemplifi es Asahi Kasei’s unique ability to integrate innovation with global operations,” said Shinomiya. “We will continue evolving with a global perspective to drive growth and enhance patient care worldwide.”
More information online:
ilmt.co/PL/DGVW 64671pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the Europe and Middle East? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate.
Email:
info@intlabmate.com
Business
Opportunities
Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
